JP2008542431A5 - - Google Patents

Claims (10)

A compound of formula I, any isomer thereof or any mixture of isomers thereof, or a pharmaceutically acceptable salt thereof:

Where
R ^a represents hydrogen or alkyl, which alkyl consists of halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl Optionally substituted by one or more substituents independently selected from the group; and R ^b represents an aryl group, which aryl group is halo, trifluoromethyl, trifluoromethoxy, cyano , Nitro, hydroxy, alkoxy, cycloalkoxy, alkoxyalkyl, cycloalkoxyalkyl, methylenedioxy, ethylenedioxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkenyl, —NR′R ″, — (C═O ) NR'R "or- R ′ (C═O) R ″ may be substituted by one or more substituents independently selected from the group consisting of; R ′ and R ″ are each independently Represents hydrogen or alkyl. R ^a represents hydrogen or alkyl, A compound according to claim 1. R ^b represents a phenyl group, which may be substituted with one or more substituents independently selected from the group consisting of halo, trifluoromethyl, trifluoromethoxy, cyano and alkoxy. The compound according to claim 1 or 2, which is good. ^Rb represents a phenyl group, which is substituted with two substituents independently selected from the group consisting of halo, trifluoromethyl, trifluoromethoxy, cyano and alkoxy. 2. The compound according to 2. R ^b represents a naphthyl group, which may be substituted with one or more substituents independently selected from the group consisting of halo, trifluoromethyl, trifluoromethoxy, cyano and alkoxy. The compound according to claim 1 or 2, which is good. Exo-3- (3,4-dichloro-phenoxy) -8-aza-bicyclo [3.2.1] oct-6-ene;
Exo-3- (3-bromo-4-chloro-phenoxy) -8-aza-bicyclo [3.2.1] oct-6-ene;
Exo-3- (6-methoxy-naphthalen-2-yloxy) -8-aza-bicyclo [3.2.1] oct-6-ene;
Exo-3- (3-chloro-4-fluoro-phenoxy) -8-aza-bicyclo [3.2.1] oct-6-ene;
Exo-3- (4-bromo-3-chloro-phenoxy) -8-aza-bicyclo [3.2.1] oct-6-ene;
Exo-3- (4-chloro-3-fluoro-phenoxy) -8-aza-bicyclo [3.2.1] oct-6-ene;
Exo-3- (3,4-dichloro-phenoxy) -8-methyl-8-aza-bicyclo [3.2.1] oct-6-ene;
Exo-3- (3-bromo-4-chloro-phenoxy) -8-methyl-8-aza-bicyclo [3.2.1] oct-6-ene;
Exo-3- (6-methoxy-naphthalen-2-yloxy) -8-methyl-8-aza-bicyclo [3.2.1] oct-6-ene;
Exo-3- (3-chloro-4-fluoro-phenoxy) -8-methyl-8-aza-bicyclo [3.2.1] oct-6-ene;
Exo-3- (4-bromo-3-chloro-phenoxy) -8-methyl-8-aza-bicyclo [3.2.1] oct-6-ene;
Exo-3- (4-chloro-3-fluoro-phenoxy) -8-methyl-8-aza-bicyclo [3.2.1] oct-6-ene;
Or a pharmaceutically acceptable salt thereof.   7. A therapeutically effective amount of the compound of any one of claims 1-6, any isomer thereof or any mixture of isomers thereof, or at least one pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient or diluent. A pharmaceutical composition comprising the compound according to any one of claims 1 to 6, any isomer thereof or a mixture of any of the isomers, or a pharmaceutically acceptable salt thereof . A pharmaceutical composition for treating, preventing or alleviating a disease or disorder or symptom of a mammal, including a human, wherein the disease, disorder or symptom responds to inhibition of monoamine neurotransmitter reuptake in the central nervous system disease, Ru disorder or condition der pharmaceutical composition according to claim 8. Disease, disorder or symptom is mood disorder, depression, atypical depression, secondary depression for pain, major depression, mood modulation, bipolar disorder, bipolar I disorder, bipolar II disorder, mood Circulatory disorder, mood disorder due to general medical condition, substance-induced mood disorder, pseudodementia, Ganza syndrome, threatened disorder, panic disorder, panic disorder without agoraphobia, panic disorder with agoraphobia, panic Agoraphobia without history of disability, panic attack, memory deficit, memory loss, attention deficit hyperactivity disorder, obesity, anxiety, generalized anxiety disorder, eating disorder, Parkinson's disease, parkinsonism, dementia, addiction Age-related dementia, senile dementia, Alzheimer's disease, acquired immune deficiency syndrome, cognitive syndrome, memory dysfunction due to aging, specific phobia, social phobia, social anxiety disorder, trauma Stress disorder, acute stress disorder, drug addiction, drug abuse, cocaine abuse, nicotine abuse, tobacco abuse, alcoholism, alcoholism, stealing, pain, chronic pain, inflammatory pain, neuropathic pain Migraine, tension headache, chronic tension headache, pain with depressive symptoms, fibromyalgia, arthritis, osteoarthritis, rheumatoid arthritis, back pain, cancer pain, irritable bowel pain, irritable bowel syndrome, surgery Post-pain, post-mastectomy pain syndrome (PMPS), post-stroke pain, drug-induced neuropathy, diabetic neuropathy, sympathetic nerve-dependent pain, trigeminal neuralgia, toothache, fascia pain, phantom limb pain, bulimia, menstruation Pre-syndrome, premenstrual dysphoric disorder, late luteal phase mental symptoms, post-traumatic syndrome, chronic fatigue syndrome, urinary incontinence, stress urinary incontinence, urge incontinence, nocturnal urinary incontinence, sexual dysfunction, premature ejaculation Disease, erectile dysfunction, early-onset female orgasm, restless leg syndrome, periodic limb movement disorder, eating disorder, anorexia nervosa, sleep disorder, pervasive developmental disorder, autism, Asperger disorder, let's disorder, Childhood disintegration disorder, learning disorder, motor skill disorder, speechlessness, hair loss, narcolepsy, post-stroke depression, seizure-induced brain injury, seizure-induced nerve injury, Gildlerette disease, tinnitus, tic disorder, body dysmorphic disorder The pharmaceutical composition according to claim 9, which is a rebellious challenge disorder or a post-seizure disorder.